Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma

Trial Profile

Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs CMB 305 (Primary) ; Cyclophosphamide (Primary) ; Interleukin-2 (Primary) ; LV 305 (Primary) ; T lymphocyte cell therapies (Primary)
  • Indications Liposarcoma; Sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jul 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 02 Jul 2018 Planned primary completion date changed from 2 Jun 2018 to 1 Dec 2019.
    • 02 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top